Management of Anxiety in Parkinson's Disease
Movement Disorders Clinical Practice · 2025-10 · 12 (10) · 1490-1501
DOI: 10.1002/mdc3.70144 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 26.06.2025. Verfasst von Alex J Berry und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Anxiety, Anti-Anxiety Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anxiety is a common, distressing, hard‐to‐diagnose and hard‐to‐treat symptom in Parkinson's disease. No formal guidelines exist to assist management.
Objective
We provide a pragmatic guide to detecting and managing anxiety in Parkinson's disease.
Methods
In this educational review, we describe the phenomenology, diagnostic challenges, hypothesized neurobiology, and the rationale for treatments for anxiety in Parkinson's disease. We review the major drug‐classes and non‐pharmacological treatment approaches in current use. We also present a meta‐analysis of pharmacological treatments of anxiety derived from previously published systematic reviews of RCTs for depression in Parkinson's disease in which anxiety was a secondary outcome.
Results
In our meta‐analysis, anxiolytic medications showed a moderate overall anxiolytic effect compared to placebo (standardized mean difference: −0.45 [95% CI: −0.78, −0.12], p = 0.02). There were significant limitations with the studies included in this meta‐analysis, with studies generally having small cohort sizes, and each specific pharmacotherapy was not studied in more than one randomized control trial. We also describe a pragmatic algorithm for individualized pharmacological management, based on our own experience of selecting treatments to optimize side‐effect profile and treatment of comorbid symptoms.
Conclusions
Detecting and treating anxiety likely benefits people with Parkinson's disease, though the current evidence‐base for specific treatments or specific pharmacotherapy remains limited. Further work is needed to investigate the different evidence‐based approaches for managing anxiety in Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
- Division of Psychiatry, University College London, London, United Kingdom.
- Unidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain.
- UCL Queen Square Institute of Neurology, University College London, London, UK.
ORCID-Profile: Alex J Berry, Ashwani Jha
Zitieren
APA
Berry, A. J., Costello, H., Jesús, S., Price, G., & Jha, A. (2025). Management of Anxiety in Parkinson's Disease. Movement Disorders Clinical Practice, 12(10), 1490-1501. https://doi.org/10.1002/mdc3.70144
Vancouver
Berry AJ, Costello H, Jesús S, Price G, Jha A. Management of Anxiety in Parkinson's Disease. Movement Disorders Clinical Practice. 2025;12(10):1490-1501. doi:10.1002/mdc3.70144
BibTeX
@article{Berry2025,
author = {Berry, Alex J and Costello, Harry and Jesús, Silvia and Price, Gary and Jha, Ashwani},
title = {Management of Anxiety in Parkinson's Disease},
journal = {Movement Disorders Clinical Practice},
year = {2025},
volume = {12},
number = {10},
pages = {1490--1501},
doi = {10.1002/mdc3.70144}
}
EUVIMED